[Drug name]

Generic name: Epalrestat 50mg Tablets

English name: Epalrestat 50mg Tablets

[Ingredients] The main ingredient of this product is Epalrestat, and its chemical name is: 5-[(1Z, 2E)-2-methyl-3-phenyl-2-propenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid

[Description] Iron-red film-coated tablets, orange-yellow color after removal of the coating.

[Indications] Diabetic neuropathy.

[Posology and method of administration] The usual adult dose is 50mg (1 tablet), three times a day, orally before meals.

[Pharmacological Effect]

Epalrestat is a reversible, non-competitive inhibitor of aldose reductase with selective inhibition of aldose reductase. Clinical studies have shown that Epalrestat can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, and improve subjective symptoms and neurological dysfunction compared with the control group. The results of animal tests showed that Epalrestat significantly inhibited the accumulation of sorbitol in the sciatic nerve, erythrocytes, and retina of the diabetic model rats, and improved the motor nerve conduction velocity and autonomic function; in terms of neuromorphology, Epalrestat improved the abnormal axonal flow, increased the density of myelinated nerve fibers in the sciatic nerve, the thickness of peroneal nerve myelin sheath, axonal area, and axonal cylindrical rate; in addition, Epalrestat also improved the blood flow in the sciatic nerve of the model animals and brought back the inositol content.

[Storage] Store at room temperature (10 ~ 30 ℃).

[Packaging] Soft double aluminum package, 10 tablets/blister; 12 tablets/blister.

[Shelf Life] 36 months.